Funding for this research was provided by:
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Received: 25 April 2021
Accepted: 14 August 2021
First Online: 21 August 2021
: The authors declare no conflict of interest regarding the submitted work. Regarding interactions outside the submitted work, Professor Dr. Julia Caroline Radosa has received travel grants from Medac GmbH (Wedel, Germany), Gedeon Richter (Budapest, Hungary), and Celgene (Summit, USA), Daiichi Sankyo (Tokio, Japan), Pfizer (New York City, USA) and was an honorary speaker for Pfizer (New York City, USA) and Clovis Oncology in the past. Dr. Lisa Stotz has received travel grants from Medac GmbH (Wedel, Germany) and Celgene (Summit, USA) outside the submitted work in the past. Dr. Julia Sarah Maria Zimmermann was an honorary speaker for Clovis Oncology in the past. Dr. Panagiotis Sklavounos was an honorary speaker for Pfizer, Astra Zeneca, Clovis Oncology und KLS Martin in the past. Professor Dr. Erich–Franz Solomayer is receiving grants from the University of Saarland, Storz, and Erbe; personal fees and other compensation from Roche (Basel, Switzerland), Pfizer (New York City, USA), Celgene (Summit USA), Amgen (Thousand Oaks, USA), and Astra Zeneca (Cambridge, GB); other fees from Johnson & Johnson (New Brunswick, USA), Novartis (Basel, Switzerland), Tesaro (Waltham, USA), Medac GmbH (Wedel, Germany), MSD (Kenilworth, USA), Vifor (Sankt Gallen, Switzerland), Gedeon Richter (Budapest, Hungary), Takeda (Tokyo, Japan), and AGE (Buchholz, Germany) outside the submitted work.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University of Saarland (Date 16.02.2018/No. 19/18).
: Informed consent was obtained from all patients included in the study.
: The authors affirm that all patients provided consent for publication.